Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discusses a study which evaluated risk of relapse and survival outcomes of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving post-transplant cyclophosphamide versus standard graft-versus-host disease (GvHD) prophylaxis. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.